Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
61Cu-NODAGA-PSMA for Prostate Cancer Imaging
NCT06736054Phase 1Recruiting
- Sponsor
- Hoag Memorial Hospital Presbyterian
- Start
- Oct 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 61Cu-NODAGA-PSMA in prostate adenocarcinoma, sponsored by Hoag Memorial Hospital Presbyterian. Primary endpoint: Incidence of Imaging Agent-Emergent Adverse Events at 24 hours. Started Oct 2024; status: recruiting.
02
Drugs
61Cu-NODAGA-PSMA
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT06736054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06736054.